Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177021 · ClinicalTrials.gov registry record · Phase 4
Aldara for the Treatment of Extensive Alopecia Areata
A Phase 4 study of Alopecia Areata, sponsored by Hordinsky, Maria K., MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00177021: Completed Phase 4 study of Alopecia Areata, sponsored by Hordinsky, Maria K., MD.
NCT00177021 is a Phase 4 study of Alopecia Areata that has completed, run by Hordinsky, Maria K., MD. The registered enrollment target is 20 participants, below the 1,954-participant average among 26 other Alopecia Areata trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00177021, a Phase 4 study of Alopecia Areata, has completed, sponsored by Hordinsky, Maria K., MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
We propose to examine the efficacy and tolerability of Aldara Cream 5% for the treatment of extensive alopecia areata. Aldara is a immune-response modifier. The drug induces the production of cytokines which are small, hormone-like proteins involved in cellular communication during immune responses. We hypothesize that this drug will effect the inflammatory cells present around hair follicles in patients with alopecia areata.
Conditions Studied
Interventions
- DRUG Aldara Cream 5%
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2000-10 |
| Est. Completion | 2002-08 |
| Phase | Phase 4 |
What the finished NCT00177021 record still lists
NCT00177021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,954-participant average among 26 other Alopecia Areata trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 1 intervention - of which Aldara Cream 5% is the first listed.
NCT00177021 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00177021 about?
NCT00177021 is a clinical study titled "Aldara for the Treatment of Extensive Alopecia Areata". We propose to examine the efficacy and tolerability of Aldara Cream 5% for the treatment of extensive alopecia areata. Aldara is a immune-response modifier. The drug induces the production of cytokines which are small, hormone-like proteins involved in cellular communication during immune responses....
What is the current status of trial NCT00177021?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2000-10. Estimated completion is 2002-08.
What conditions does trial NCT00177021 study?
This clinical trial studies the following conditions: Alopecia Areata.
What interventions are being tested in trial NCT00177021?
The interventions under investigation include: Aldara Cream 5% (DRUG).
Who is sponsoring clinical trial NCT00177021?
This trial is sponsored by Hordinsky, Maria K., MD, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00177021 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00177021's enrollment target sits among peer trials
20 22nd of 26 higher than 5 of 26 other Alopecia Areata trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alopecia Areata trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
RECRUITING · Phase 2
-
A Study of LAD603 in Adults With Alopecia Areata
RECRUITING · Phase 2
-
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
RECRUITING · Phase 1
-
CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
RECRUITING
-
Dupilumab in the Treatment of Pediatric Alopecia Areata
RECRUITING · Phase 2
-
Intralesional Cyclosporine for Alopecia Areata
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia